侵袭性变异型前列腺癌与治疗相关神经内分泌前列腺癌的预后及治疗反应:系统综述与荟萃分析
该系统综述与荟萃分析检索了PubMed、Embase和Scopus至2025年9月15日的文献,最终纳入40项研究(含10篇摘要),评估侵袭性变异型前列腺癌(AVPC)不同定义下的预后及治疗反应。结果显示,临床定义或分子定义的AVPC(c-AVPC/m-AVPC)相比非AVPC患者进展风险和死亡风险更高;铂类化疗在AVPC各亚型中客观缓解率优于非铂方案,且在c-AVPC/m-AVPC中与更长的无进展生存和总生存相关。
要点
- c-AVPC/m-AVPC相比非AVPC与更短的无进展生存和总生存相关。
- 铂类化疗在AVPC总体及c-AVPC/m-AVPC、t-NEPC亚组中客观缓解率均高于非铂方案。
- c-AVPC/m-AVPC中铂类化疗与更长的无进展生存和总生存相关,t-NEPC数据不足。
核心结论
- AVPC涵盖晚期前列腺癌的不同亚群,接受标准前列腺癌治疗时进展和死亡风险更高。
- 铂类化疗与AVPC各亚型更好的缓解率相关,且在c-AVPC和m-AVPC中似有生存获益。
研究设计与样本
- 系统文献检索PubMed、Embase和Scopus至2025年9月15日,最终分析40项研究(含10篇摘要)。
- 纳入报告AVPC患者生存结局和治疗反应的研究进行荟萃分析。
主要发现
- c-AVPC/m-AVPC相比非AVPC与更短的无进展生存相关(HR 2.72,95%CI 1.54-4.81;I2=0%)。
- c-AVPC/m-AVPC相比非AVPC与更短的总生存相关(HR 2.81,95%CI 1.87-4.22;I2=36%)。
- 铂类化疗在AVPC总体队列中客观缓解率高于非铂方案(46% vs 19%;p<0.01)。
- c-AVPC/m-AVPC亚组中铂类化疗客观缓解率高于非铂方案(41% vs 16%;p=0.04)。
- t-NEPC亚组中铂类化疗客观缓解率高于非铂方案(49% vs 22%;p<0.01)。
关键数值与推荐
- c-AVPC/m-AVPC中铂类化疗与非铂方案相比,无进展生存HR 0.39(95%CI 0.24-0.62;I2=0%)。
- c-AVPC/m-AVPC中铂类化疗与非铂方案相比,总生存HR 0.40(95%CI 0.23-0.68;I2=0%)。
- t-NEPC中按铂类化疗使用比较无进展生存和总生存的数据不足,无法进行荟萃分析。
临床怎么用
- 对c-AVPC/m-AVPC患者,铂类化疗可能改善缓解率及生存,可考虑作为治疗选择。
- t-NEPC患者铂类化疗缓解率更高,但生存获益证据不足,需个体化决策。
- 未来应结合基因组学、组织学和先进影像的分子分类框架优化患者分层和靶向治疗。
局限性
- AVPC定义仍存在异质性,缺乏统一标准。
- 纳入研究包含10篇摘要,可能影响证据质量。
- t-NEPC中按铂类化疗使用比较生存结局的数据不足,无法进行荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Aggressive-variant prostate cancer (AVPC) is an umbrella term that encompasses clinically defined AVPC (c-AVPC), molecularly defined AVPC (m-AVPC), and treatment-related neuroendocrine PC (t-NEPC), which represent a spectrum of metastatic castration-resistant PC phenotypes with poor clinical outcomes. Despite its clinical relevance, AVPC definitions remain heterogeneous and treatment guidelines are lacking. Our aim was to elucidate AVPC prognosis and treatment responsiveness across definitions. METHODS: We conducted a systematic literature search of PubMed, Embase, and Scopus up to September 15, 2025. Our meta-analysis included studies reporting survival outcomes and treatment responses for patients with AVPC. KEY FINDINGS AND LIMITATIONS: From 1518 records, 40 studies (including 10 abstracts) were analyzed. In comparison to non-AVPC, c-AVPC/m-AVPC was associated with shorter progression-free survival (PFS; hazard ratio [HR] 2.72, 95% confidence interval [CI] 1.54-4.81; I2 = 0%) and overall survival (OS; HR 2.81, 95% CI 1.87-4.22; I2 = 36%). Platinum-based chemotherapy (PBC) outperformed non-platinum regimens, with higher objective response rates in the overall AVPC cohort (46% vs 19%; p < 0.01) and in the c-AVPC/m-AVPC (41% vs 16%; p = 0.04) and t-NEPC (49% vs 22%; p < 0.01) subgroups. In c-AVPC/m-AVPC, PBC was associated with longer PFS (HR 0.39, 95% CI 0.24-0.62; I2 = 0%) and OS (HR 0.40, 95% CI 0.23-0.68; I2 = 0%) according to evidence from mixed-design studies. For t-NEPC, data were insufficient for meta-analytic comparison of PFS and OS by PBC use. CONCLUSIONS AND CLINICAL IMPLICATIONS: AVPC encompasses distinct subsets of advanced PC that are associated with higher risk of progression and death on standard PC therapies. Platinum-based chemotherapy was associated with better response rates across AVPC subtypes and appears to confer a survival benefit in c-AVPC and m-AVPC. Future studies should focus on molecularly informed classification frameworks that include genomics, histology, and advanced imaging to optimize patient stratification and guide targeted therapies.
引用
- Pedrani M, Salfi G, Pecoraro G, et al. Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2026. PMID: 41672832. doi:10.1016/j.euo.2026.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。